Evidence map›Paper›PMID 25147582›Full record

ArticleDiabetology & metabolic syndrome2014

Metabolic profile response to administration of epigallocatechin-3-gallate in high-fat-fed mice.

Mayara Franzoi Moreno, Rachel De Laquila, Marcos Hiromu Okuda, Fábio Santos Lira, Gabriel Inácio de Morais Honorato de Souza, Cláudio Teodoro de Souza, Monica Marques Telles, Eliane Beraldi Ribeiro, Claudia Maria Oller do Nascimento, Lila Missae Oyama

Open access · goldAbstract read
In one paragraph

Article in Diabetology & metabolic syndrome, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mayara Franzoi MorenoDepartamento de Fisiologia, Universidade Federal de São Paulo-EPM, São Paulo, SP Brasil.
Rachel De LaquilaDepartamento de Fisiologia, Universidade Federal de São Paulo-EPM, São Paulo, SP Brasil ; Faculdades Integradas Coração de Jesus - FAINC, Santo André, SP Brasil.
Marcos Hiromu OkudaDepartamento de Fisiologia, Universidade Federal de São Paulo-EPM, São Paulo, SP Brasil.
Fábio Santos LiraImmunometabolism Research Group, Department of Physical Education, Universidade Estadual Paulista, UNESP, Presidente Prudente, SP Brazil.
Gabriel Inácio de Morais Honorato de SouzaDepartamento de Fisiologia, Universidade Federal de São Paulo-EPM, São Paulo, SP Brasil.
Cláudio Teodoro de SouzaLaboratory of Exercise Biochemistry and Physiology, Health Sciences Unit, University of Southern Santa Catarina, Criciúma, SC Brazil.
Monica Marques TellesDepartamento de Ciências Biológicas, Universidade Federal de São Paulo-Campus Diadema, Diadema, SP Brasil.
Eliane Beraldi RibeiroDepartamento de Fisiologia, Universidade Federal de São Paulo-EPM, São Paulo, SP Brasil.
Claudia Maria Oller do NascimentoDepartamento de Fisiologia, Universidade Federal de São Paulo-EPM, São Paulo, SP Brasil.
Lila Missae OyamaDepartamento de Fisiologia, Universidade Federal de São Paulo-EPM, São Paulo, SP Brasil.
Universidade Federal de São Paulo · BRUniversidade do Sul de Santa Catarina · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObesity is associated with increased adipose tissue and glucose intolerance. High-fat diets (HFDs) are known to induce obesity and increase proinflammatory adipokines. The consumption of green tea may improve the health of obese individuals because it contains a potent antioxidant that has effects on body weight, energy expenditure and serum cholesterol concentrations.

methodsWe examined the effects of epigallocatechin-3-gallate (EGCG) (50 mg/kg body weight per day) or saline after 30 or 60 days of treatment. Mice were distributed into four groups: 1) NS: normolipidic diet receiving saline; 2) NE: normolipidic diet receiving EGCG; 3) HFS: high-fat diet receiving saline; 4) HFE: high-fat diet receiving EGCG.

resultsWe observed that administration of a HFD plus EGCG treatment for 60 days reduced delta weight, the relative weights of the mesenteric adipose tissue (MES), retroperitonial adipose tissue (RET), epididymal adipose tissue (EPI), the sum of the adipose tissues (SAT), reduced triacylglycerol (TG) and improved both high-density lipoprotein (HDL) cholesterol levels and the adiponectin/STA ratio when compared with HFS.

conclusionsOur results suggest that the chronic administration of EGCG (60 days) promoted a significant improvement in glucose tolerance, decreased adipose tissue deposits, weight mass, TG and HDL-C only when associated with high-fat diet treatment.

Indexed as

AdipokinesAdipose tissueHigh-fat dietInflammation

Identifiers

PMID25147582
PMCPMC4139607
OpenAlexW2170495501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.